626 related articles for article (PubMed ID: 30207748)
1. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.
Akturk HK; Snell-Bergeon JK; Rewers A; Klaff LJ; Bode BW; Peters AL; Bailey TS; Garg SK
Diabetes Technol Ther; 2018 Oct; 20(10):639-647. PubMed ID: 30207748
[TBL] [Abstract][Full Text] [Related]
2. Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial.
Bode BW; McGill JB; Lorber DL; Gross JL; Chang PC; Bregman DB;
Diabetes Care; 2015 Dec; 38(12):2266-73. PubMed ID: 26180109
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Mathieu C; Bode BW; Franek E; Philis-Tsimikas A; Rose L; Graungaard T; Birk Østerskov A; Russell-Jones D
Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes.
Beck RW; Russell SJ; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro C; Li Z; Calhoun P
Diabetes Technol Ther; 2022 Oct; 24(10):681-696. PubMed ID: 36173235
[No Abstract] [Full Text] [Related]
5. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effect of insulin glulisine to insulin aspart on breakfast postprandial blood glucose levels in children with type 1 diabetes mellitus on multiple daily injections.
Cemeroglu AP; Kleis L; Wood A; Parkes C; Wood MA; Davis AT
Endocr Pract; 2013; 19(4):614-9. PubMed ID: 23425652
[TBL] [Abstract][Full Text] [Related]
7. Impact of Fast-Acting Insulin Aspart on Glycemic Control in Patients with Type 1 Diabetes Using Intermittent-Scanning Continuous Glucose Monitoring Within a Real-World Setting: The GoBolus Study.
Danne T; Axel Schweitzer M; Keuthage W; Kipper S; Kretzschmar Y; Simon J; Wiedenmann T; Ziegler R
Diabetes Technol Ther; 2021 Mar; 23(3):203-212. PubMed ID: 32924568
[No Abstract] [Full Text] [Related]
8. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
Russell-Jones D; Bode BW; De Block C; Franek E; Heller SR; Mathieu C; Philis-Tsimikas A; Rose L; Woo VC; Østerskov AB; Graungaard T; Bergenstal RM
Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319
[TBL] [Abstract][Full Text] [Related]
9. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.
Ohta A; Arai K; Nishine A; Sada Y; Kato H; Fukuda H; Asai S; Nagai Y; Katabami T; Tanaka Y
Endocr J; 2013; 60(2):173-7. PubMed ID: 23047542
[TBL] [Abstract][Full Text] [Related]
10. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
Beck RW; Riddlesworth T; Ruedy K; Ahmann A; Bergenstal R; Haller S; Kollman C; Kruger D; McGill JB; Polonsky W; Toschi E; Wolpert H; Price D;
JAMA; 2017 Jan; 317(4):371-378. PubMed ID: 28118453
[TBL] [Abstract][Full Text] [Related]
11. A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 Diabetes.
Kruger D; Kass A; Lonier J; Pettus J; Raskin P; Salam M; Trikudanathan S; Zhou K; Russell SJ; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro C; Li Z; Marak MC; Calhoun P; Beck RW
Diabetes Technol Ther; 2022 Oct; 24(10):697-711. PubMed ID: 36173236
[No Abstract] [Full Text] [Related]
12. Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial.
Messer LH; Buckingham BA; Cogen F; Daniels M; Forlenza G; Jafri RZ; Mauras N; Muir A; Wadwa RP; White PC; Russell SJ; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro CA; Li Z; Marak MC; Calhoun P; Beck RW
Diabetes Technol Ther; 2022 Oct; 24(10):712-725. PubMed ID: 36173237
[No Abstract] [Full Text] [Related]
13. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Feb; 22(2):85-95. PubMed ID: 31804851
[No Abstract] [Full Text] [Related]
15. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
Bode BW; Iotova V; Kovarenko M; Laffel LM; Rao PV; Deenadayalan S; Ekelund M; Larsen SF; Danne T
Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
[TBL] [Abstract][Full Text] [Related]
16. Hypoglycaemia is reduced with use of inhaled Technosphere
Seaquist ER; Blonde L; McGill JB; Heller SR; Kendall DM; Bumpass JB; Pompilio FM; Grant ML
Diabet Med; 2020 May; 37(5):752-759. PubMed ID: 31811662
[TBL] [Abstract][Full Text] [Related]
17. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
[TBL] [Abstract][Full Text] [Related]
18. Understanding inhaled Technosphere Insulin: Results of an early randomized trial in type 1 diabetes mellitus.
McGill JB; Weiss D; Grant M; Jones MC; Kendall DM; Hoogwerf BJ
J Diabetes; 2021 Feb; 13(2):164-172. PubMed ID: 32737923
[TBL] [Abstract][Full Text] [Related]
19. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
Buse JB; Carlson AL; Komatsu M; Mosenzon O; Rose L; Liang B; Buchholtz K; Horio H; Kadowaki T
Diabetes Obes Metab; 2018 Dec; 20(12):2885-2893. PubMed ID: 30259644
[TBL] [Abstract][Full Text] [Related]
20. Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective.
Senior P; Hramiak I
Can J Diabetes; 2019 Oct; 43(7):515-523. PubMed ID: 30872107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
